Immunotherapy and cardiovascular diseases: novel avenues for immunotherapeutic approaches

8Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

As current therapies for cardiovascular disease (CVD), predominantly based on lipid lowering, still face an unacceptable residual risk, novel treatment strategies are being explored. Besides lipids, inflammatory processes play a major role in the pathogenesis of atherosclerosis, the underlying cause of the majority of CVD. The first clinical trials targeting the interleukin-1β-inflammasome axis have shown that targeting this pathway is successful in reducing cardiovascular events but did not decrease overall CVD mortality. Hence, novel and improved immunotherapeutics to treat CVD are being awaited.

References Powered by Scopus

Antiinflammatory therapy with canakinumab for atherosclerotic disease

6494Citations
N/AReaders
Get full text

The pro- and anti-inflammatory properties of the cytokine interleukin-6

2507Citations
N/AReaders
Get full text

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

2335Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bonfiglio, C. A., Weber, C., Atzler, D., & Lutgens, E. (2023, April 1). Immunotherapy and cardiovascular diseases: novel avenues for immunotherapeutic approaches. QJM: An International Journal of Medicine . Oxford University Press. https://doi.org/10.1093/qjmed/hcab207

Readers over time

‘22‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

50%

Immunology and Microbiology 1

50%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0